In the Media
Are you looking for the latest media coverage of the BioMed X Institute, its research projects and people behind the innovation model? Here you will find the latest clippings – hot off the press!
Visit: AION Labs, In Continued Partnership with BioMed X, Launches First 2024 Global Call for Applications: AI/ML Platform for Targeting RNA with Small Molecules
AION Labs, In Continued Partnership with BioMed X, Launches First 2024 Global Call for Applications: AI/ML Platform for Targeting RNA with Small Molecules
BNN
AION Labs, collaborating with industry leaders, invites innovators to join their mission in leveraging AI and ML to target RNA for small molecule therapeutics. This initiative could redefine drug discovery and benefit global health.
Visit: AION Labs, In Continued Partnership with BioMed X, Launches First 2024 Global Call for Applications: AI/ML Platform for Targeting RNA with Small Molecules
AION Labs, In Continued Partnership with BioMed X, Launches First 2024 Global Call for Applications: AI/ML Platform for Targeting RNA with Small Molecules
PR Newswire
Israel-Based Venture Studio Comprising AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund, Amiti Ventures and Amazon Web Services (AWS) Seeks Global Research and Technology Talent to Form New Startup Focused on: “AI/ML Platform for Targeting RNA with Small Molecules”
Visit: AION Labs, In Continued Partnership with BioMed X, Launches First 2024 Global Call for Applications: AI/ML Platform for Targeting RNA with Small Molecules
AION Labs, In Continued Partnership with BioMed X, Launches First 2024 Global Call for Applications: AI/ML Platform for Targeting RNA with Small Molecules
PharmiWeb
Israel-Based Venture Studio Comprising AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund, Amiti Ventures and Amazon Web Services (AWS) Seeks Global Research and Technology Talent to Form New Startup Focused on: “AI/ML Platform for Targeting RNA with Small Molecules“